Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Kim CG, Ann Oncol. 2019…
この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Kim CG, Ann Oncol. 2019…
この記事を読む
Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy. Sa…
この記事を読む
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Schu…
この記事を読む
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. Hendriks LE…
この記事を読む
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. Vojnic M et al. J…
この記事を読む
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). Jeanson A et al. J Thorac On…
この記事を読む
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Schoenfeld AJ et al. A…
この記事を読む
Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Galli …
この記事を読む
Clinical features and outcomes of pulmonary lymphoma: A single center experience of 180 cases. Zhang MC et al. Lung Canc…
この記事を読む
Randomized phase II study of Pemetrexed or Pemetrexed plus bevacizumab for elderly patients with previously untreated no…